Humana Will Yank Obamacare Plans Serving 100000 Patients

8 Nov 2015 | Author: | No comments yet »

Humana Inc (HUM) Releases FY15 Earnings Guidance.

As is usual for this time of year, my mailbox and email are being flooded with advertisements to get me to switch from Original Medicare to a Medicare Advantage plan. The company provided earnings per share (EPS) guidance of $7.75 for the period, compared to the Thomson Reuters consensus estimate of $7.76, AnalystRatingsNetwork.com reports.

They had the implied threat that if more of their patients didn’t switch Medicare Advantage, which is more profitable for them, they might not take Medicare patients anymore. Susquehanna reduced their price objective on Humana from $215.00 to $213.00 and set a neutral rating for the company in a research note on Thursday, July 9th.

The Federal Trade Commission is warning people about ruses like these: Someone calls and says you must join their prescription plan or you’ll lose your Medicare coverage. The Company’s medical and specialty insurance products enable associates to gain access to healthcare services through its network healthcare providers. Its Company Group segment contains products sold to company groups, including medical and supplemental benefit plans, in addition to health and wellness products.

Its Healthcare Services section includes companies, which offers services, including pharmacy solutions, provider services, home-based services, integrated behavioral health services, and predictive modeling and informatics services to other Humana companies, together with external health plan members, external health plans, and other companies or people. Receive News & Ratings for Humana Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana and related companies with MarketBeat.com’s FREE daily email newsletter.

Here you can write a commentary on the recording "Humana Will Yank Obamacare Plans Serving 100000 Patients".

* Required fields
All the reviews are moderated.
Twitter-news
Our partners
Follow us
Contact us
Our contacts

About this site